A novel negamycin analogue for the treatment of multi-drug resistant gram-negative bacterial infection
Ended Project Grant Awarded Last action
- Award ID
- W81XWH1910308
- Recipient
-
Appili Therapeutics Inc. UEI M6M7UQZCXG47
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $894,367
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- 2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$2,134,095 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $3,028,462 |
Quick answers
Who received award W81XWH1910308?
W81XWH1910308 was awarded to Appili Therapeutics Inc. by Defense Health Agency (Department of Defense) on July 1, 2019.
How much is award W81XWH1910308 worth?
$894,367 has been obligated on W81XWH1910308.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award